NASDAQ$PMVP
Pmv Pharmaceuticals Inc · Q1 2025 earnings
Q1 2025 earnings · · Before market open · Investor relations
Briefing
PMV Pharmaceuticals reported its first quarter 2025 financial results, highlighting progress in its PYNNACLE clinical trial and a strong cash position.
PMV Pharmaceuticals reported a net loss of $17.4 million for Q1 2025, an increase from $15.3 million in Q1 2024. The company maintained a strong cash position of $165.8 million, providing a cash runway to the end of 2026. Research and development expenses increased due to the advancement of product candidates, while general and administrative expenses decreased.
- Enrollment in the Phase 2 pivotal portion of the PYNNACLE clinical trial for rezatapopt is on track.
- An interim analysis from the Phase 2 PYNNACLE trial is expected mid-2025, with data from approximately 50 patients.
- Cash, cash equivalents, and marketable securities totaled $165.8 million as of March 31, 2025, providing a cash runway until the end of 2026.
- Net loss for the quarter increased to $17.5 million from $15.3 million in the prior year, primarily due to higher R&D expenses.
Headline financials
Revenue & EPS history
PMV Pharma · Revenue · Quarterly
$0
Forward guidance
PMV Pharmaceuticals expects to provide interim analysis data from the Phase 2 PYNNACLE trial in mid-2025 and anticipates its current cash position will fund operations until the end of 2026.
Tailwinds
- Enrollment for the registrational PYNNACLE trial is progressing well and remains on track.
- Interim analysis data from the Phase 2 PYNNACLE trial is expected mid-2025.
- The company has sufficient cash, cash equivalents, and marketable securities to fund operations until the end of 2026.
- Rezatapopt has been granted Fast Track designation by the FDA for patients with locally advanced or metastatic solid tumors with a p53 Y220C mutation.
- The company continues to advance its product candidates, supported by increased R&D investment.
Headwinds
- The company continues to incur net losses, with an increase in the current quarter compared to the prior year.
- Increased R&D expenses reflect ongoing investment in product candidates, which may continue to impact profitability in the short term.
- The success of the PYNNACLE trial and future product candidates is subject to clinical trial risks and uncertainties.
- The company's ability to obtain approval for rezatapopt as a tumor-agnostic treatment option is not guaranteed.
- Potential impacts from global pandemics, public health emergencies, or geopolitical tensions could affect clinical trials, supply chain, and operations.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q1 2025
+2.7%
Avg return
Earnings day
+3.4%
Avg return
5 days after
-1.3%
Avg return
30 days after
67%
14 / 21 earnings
Positive
+29.5%
Q2 2023
Best reaction
-18.1%
Q4 2022
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2025 | +2.0% | +8.0% | -10.7% | |
| Q3 2025 | +8.5% | +6.8% | -7.5% | |
| Q2 2025 | -4.1% | -6.6% | -3.9% | |
| Q1 2025 | +4.2% | +7.5% | +28.9% | |
| Q4 2024 | -3.6% | -10.2% | -27.0% | |
| Q3 2024 | +4.8% | +0.6% | -4.2% | |
| Q1 2024 | -5.6% | -0.9% | -23.1% | |
| Q4 2023 | +3.9% | +3.9% | -6.1% | |
| Q3 2023 | +7.5% | +19.9% | +24.2% | |
| Q2 2023 | +29.5% | +20.0% | -10.8% | |
| Q1 2023 | +11.9% | +14.7% | +8.5% | |
| Q4 2022 | -18.1% | -19.6% | -33.8% | |
| Q3 2022 | -3.7% | +11.2% | -2.6% | |
| Q2 2022 | +0.4% | -1.3% | -17.6% | |
| Q1 2022 | +2.2% | +9.0% | -13.7% | |
| Q4 2021 | +10.3% | +1.3% | +31.4% | |
| Q3 2021 | +0.4% | +2.4% | -1.6% | |
| Q2 2021 | -1.2% | -5.2% | -10.2% | |
| Q1 2021 | +12.7% | +15.6% | +18.5% | |
| Q4 2020 | +0.7% | -0.7% | -5.9% | |
| Q3 2020 | -5.1% | -5.2% | +40.3% | |
| Q2 2020 | — | — | — | |
| Q1 2020 | — | — | — | |
| Q4 2019 | — | — | — | |
| Q3 2019 | — | — | — | |
| Q2 2019 | — | — | — | |
| Q1 2019 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro